223 related articles for article (PubMed ID: 2123635)
1. Longitudinal survey of apolipoproteins and atherogenic risk in hemodialysis and continuous ambulatory peritoneal dialysis patients.
Burrell D; Antignani A; Fein PA; Goldwasser P; Mittman N; Avram MM
ASAIO Trans; 1990; 36(3):M331-5. PubMed ID: 2123635
[TBL] [Abstract][Full Text] [Related]
2. The uremic dyslipidemia: a cross-sectional and longitudinal study.
Avram MM; Goldwasser P; Burrell DE; Antignani A; Fein PA; Mittman N
Am J Kidney Dis; 1992 Oct; 20(4):324-35. PubMed ID: 1415199
[TBL] [Abstract][Full Text] [Related]
3. The impact of CAPD treatment on lipid metabolism and cardiovascular risk.
Tan D; Fein PA; Antignani A; Mittman N; Avram MM
Adv Perit Dial; 1990; 6():233-7. PubMed ID: 1982815
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P
Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
[TBL] [Abstract][Full Text] [Related]
5. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
[TBL] [Abstract][Full Text] [Related]
6. Fall of cholesterol with time on dialysis: impact on atherogenicity.
Lapuz M; Avram MM; Lustig A; Goldwasser P; Antignani A; Fein PA; Mittman N
ASAIO Trans; 1989; 35(3):258-60. PubMed ID: 2597459
[TBL] [Abstract][Full Text] [Related]
7. Variability of peritoneal clearances for apolipoprotein and its relationship to susceptibility for atherosclerotic changes in CAPD.
Fein PA; Fletcher D; Antignani A; Goldwasser P; Jorden A; Lustig A; Avram MM
Adv Perit Dial; 1989; 5():185-90. PubMed ID: 2577408
[TBL] [Abstract][Full Text] [Related]
8. Lipid and apolipoproteins (ApoAI, ApoB, Apo CIII, ApoE) disturbance in hemodialysis (HD) and renal transplant (Tx) patients.
Janicki K; Solski J; Janicka L; Kimak E; Bednarek-Skublewska A; Stettner S; Molas G
Ann Univ Mariae Curie Sklodowska Med; 2004; 59(1):459-66. PubMed ID: 16146031
[TBL] [Abstract][Full Text] [Related]
9. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis.
Siamopoulos KC; Elisaf MS; Bairaktari HT; Pappas MB; Sferopoulos GD; Nikolakakis NG
Perit Dial Int; 1995; 15(8):342-7. PubMed ID: 8785232
[TBL] [Abstract][Full Text] [Related]
10. Lipids, lipoproteins and apolipoproteins abnormalities in patients undergoing dialysis.
Yang X; Wang H; Zhu Z; Deng A
J Tongji Med Univ; 1997; 17(2):126-8. PubMed ID: 9639806
[TBL] [Abstract][Full Text] [Related]
11. Lipids, lipoproteins and apolipoproteins A-I and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis.
Steele J; Billington T; Janus E; Moran J
Atherosclerosis; 1989 Sep; 79(1):47-50. PubMed ID: 2803346
[TBL] [Abstract][Full Text] [Related]
12. Concentration of Lp(a) and other apolipoproteins in predialysis, hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients.
Kimak E; Solski J; Janicka L; Ksaziek A; Janicki K
Clin Chem Lab Med; 2000 May; 38(5):421-5. PubMed ID: 10952225
[TBL] [Abstract][Full Text] [Related]
13. Increased lipoprotein (a) and its relationships with other parameters of lipoprotein metabolism in chronic renal failure treated by hemodialysis.
Yiğitoğlu MR; Polat MF; Akçay F; Ari Z; Uyanik BS; Ozilgili HM
Jpn Heart J; 1997 Jan; 38(1):83-9. PubMed ID: 9186284
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis.
Saltissi D; Morgan C; Rigby RJ; Westhuyzen J
Am J Kidney Dis; 2002 Feb; 39(2):283-90. PubMed ID: 11840368
[TBL] [Abstract][Full Text] [Related]
15. [Serum apolipoproteins A1, B and Apo A1/Apo B index in children with advanced chronic renal failure and on dialysis].
Puziewicz-Zmonarska A; Zwolińska D; Makulska I; Zmonarski SC
Pol Merkur Lekarski; 2003 Apr; 14(82):299-303. PubMed ID: 12868188
[TBL] [Abstract][Full Text] [Related]
16. Lipid abnormalities in black renal patients.
Burrell DE; Antignani A; Goldwasser P; Mittman N; Fein PA; Slater PA; Gan A; Avram MM
N Y State J Med; 1991 May; 91(5):192-6. PubMed ID: 1857570
[TBL] [Abstract][Full Text] [Related]
17. Post-dialysis retention of blood lipoproteins and apolipoproteins in patients with end-stage renal disease on maintenance haemodialysis in Kuwait.
Al-Rashidi M; Hussain AA; Nampoory MR; Al-Ali JH; Akanji AO
Clin Chim Acta; 2004 Jun; 344(1-2):149-54. PubMed ID: 15149883
[TBL] [Abstract][Full Text] [Related]
18. Ischemic heart disease, serum cholesterol, and apolipoproteins in CAPD.
Gault MH; Longerich L; Prabhakaran V; Purchase L
ASAIO Trans; 1991; 37(3):M513-4. PubMed ID: 1751258
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis.
Avram MM; Fein PA; Antignani A; Mittman N; Mushnick RA; Lustig AR; Lapuz MH; Goldwasser P
Am J Med; 1989 Nov; 87(5N):55N-60N. PubMed ID: 2486549
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature.
Gault MH; Longerich LL; Purchase L; Harnett J; Breckenridge C
Nephron; 1995; 70(2):155-70. PubMed ID: 7566298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
